skip to content
Omalizumab (Xolair) : treatment of adults and adolescents (12 years of age and above) with chronic idiopathic urticaria. Preview this item
ClosePreview this item
Checking...

Omalizumab (Xolair) : treatment of adults and adolescents (12 years of age and above) with chronic idiopathic urticaria.

Author: Canadian Agency for Drugs and Technologies in Health,
Publisher: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2015.
Series: Common drug review clinical review report.
Edition/Format:   eBook : Document : English
Summary:
The objective of this systematic review was to assess the beneficial and harmful effects of omalizumab (OMA) for the treatment of chronic idiopathic urticaria (CIU) in adults and adolescents who remain symptomatic despite H1 antihistamine treatment.
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

 

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Review
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Canadian Agency for Drugs and Technologies in Health,
OCLC Number: 956966183
Description: 1 online resource (1 PDF file) : illustrations.
Series Title: Common drug review clinical review report.

Abstract:

The objective of this systematic review was to assess the beneficial and harmful effects of omalizumab (OMA) for the treatment of chronic idiopathic urticaria (CIU) in adults and adolescents who remain symptomatic despite H1 antihistamine treatment.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/956966183> # Omalizumab (Xolair) : treatment of adults and adolescents (12 years of age and above) with chronic idiopathic urticaria.
    a schema:CreativeWork, schema:Book, schema:MediaObject ;
   library:oclcnum "956966183" ;
   library:placeOfPublication <http://id.loc.gov/vocabulary/countries/onc> ;
   schema:about <http://experiment.worldcat.org/entity/work/data/3805345431#Topic/treatment_outcome> ; # Treatment Outcome
   schema:about <http://experiment.worldcat.org/entity/work/data/3805345431#Topic/omalizumab_adverse_effects> ; # Omalizumab--adverse effects
   schema:about <http://experiment.worldcat.org/entity/work/data/3805345431#Topic/urticaria_drug_therapy> ; # Urticaria--drug therapy
   schema:about <http://experiment.worldcat.org/entity/work/data/3805345431#Topic/anti_allergic_agents_therapeutic_use> ; # Anti-Allergic Agents--therapeutic use
   schema:about <http://experiment.worldcat.org/entity/work/data/3805345431#Topic/omalizumab_therapeutic_use> ; # Omalizumab--therapeutic use
   schema:about <http://experiment.worldcat.org/entity/work/data/3805345431#Topic/adolescent> ; # Adolescent
   schema:about <http://experiment.worldcat.org/entity/work/data/3805345431#Topic/adult> ; # Adult
   schema:bookFormat schema:EBook ;
   schema:contributor <http://experiment.worldcat.org/entity/work/data/3805345431#Organization/canadian_agency_for_drugs_and_technologies_in_health> ; # Canadian Agency for Drugs and Technologies in Health,
   schema:datePublished "2015" ;
   schema:description "The objective of this systematic review was to assess the beneficial and harmful effects of omalizumab (OMA) for the treatment of chronic idiopathic urticaria (CIU) in adults and adolescents who remain symptomatic despite H1 antihistamine treatment."@en ;
   schema:exampleOfWork <http://worldcat.org/entity/work/id/3805345431> ;
   schema:genre "Review"@en ;
   schema:inLanguage "en" ;
   schema:isPartOf <http://experiment.worldcat.org/entity/work/data/3805345431#Series/common_drug_review> ; # Common drug review
   schema:isPartOf <http://experiment.worldcat.org/entity/work/data/3805345431#Series/common_drug_review_clinical_review_report> ; # Common drug review clinical review report.
   schema:name "Omalizumab (Xolair) : treatment of adults and adolescents (12 years of age and above) with chronic idiopathic urticaria."@en ;
   schema:productID "956966183" ;
   schema:url <http://www.ncbi.nlm.nih.gov/books/NBK362676/> ;
   wdrs:describedby <http://www.worldcat.org/title/-/oclc/956966183> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/3805345431#Organization/canadian_agency_for_drugs_and_technologies_in_health> # Canadian Agency for Drugs and Technologies in Health,
    a schema:Organization ;
   schema:name "Canadian Agency for Drugs and Technologies in Health," ;
    .

<http://experiment.worldcat.org/entity/work/data/3805345431#Series/common_drug_review> # Common drug review
    a bgn:PublicationSeries ;
   schema:hasPart <http://www.worldcat.org/oclc/956966183> ; # Omalizumab (Xolair) : treatment of adults and adolescents (12 years of age and above) with chronic idiopathic urticaria.
   schema:name "Common drug review" ;
    .

<http://experiment.worldcat.org/entity/work/data/3805345431#Series/common_drug_review_clinical_review_report> # Common drug review clinical review report.
    a bgn:PublicationSeries ;
   schema:hasPart <http://www.worldcat.org/oclc/956966183> ; # Omalizumab (Xolair) : treatment of adults and adolescents (12 years of age and above) with chronic idiopathic urticaria.
   schema:name "Common drug review clinical review report." ;
    .

<http://experiment.worldcat.org/entity/work/data/3805345431#Topic/anti_allergic_agents_therapeutic_use> # Anti-Allergic Agents--therapeutic use
    a schema:Intangible ;
   schema:name "Anti-Allergic Agents--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/3805345431#Topic/omalizumab_adverse_effects> # Omalizumab--adverse effects
    a schema:Intangible ;
   schema:name "Omalizumab--adverse effects"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/3805345431#Topic/omalizumab_therapeutic_use> # Omalizumab--therapeutic use
    a schema:Intangible ;
   schema:name "Omalizumab--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/3805345431#Topic/urticaria_drug_therapy> # Urticaria--drug therapy
    a schema:Intangible ;
   schema:name "Urticaria--drug therapy"@en ;
    .

<http://www.worldcat.org/title/-/oclc/956966183>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
   schema:about <http://www.worldcat.org/oclc/956966183> ; # Omalizumab (Xolair) : treatment of adults and adolescents (12 years of age and above) with chronic idiopathic urticaria.
   schema:dateModified "2017-10-21" ;
   void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.